MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-10-2025
Tonix Pharmaceuticals Holding Corp. Retained Earnings 2011-2026 | TNXP
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Tonix Pharmaceuticals Holding Corp.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -601 M | -470 M | -360 M | -268 M | -217 M | -188 M | -162 M | -141 M | -102 M | -54.3 M | -26.7 M | -15.8 M | -6.39 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -6.39 M | -601 M | -201 M |
Quarterly Retained Earnings Tonix Pharmaceuticals Holding Corp.
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -808 M | -776 M | -748 M | -731 M | -709 M | -694 M | -616 M | -601 M | -573 M | -545 M | -517 M | -470 M | -438 M | -409 M | -386 M | -360 M | -330 M | -312 M | -288 M | -268 M | -268 M | -268 M | -268 M | -217 M | -217 M | -217 M | -217 M | -188 M | -188 M | -188 M | -188 M | -162 M | -162 M | -162 M | -162 M | -141 M | -141 M | -141 M | -141 M | -102 M | -102 M | -102 M | -102 M | -54.3 M | -54.3 M | -54.3 M | -54.3 M | -26.7 M | -26.7 M | -26.7 M | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -26.7 M | -808 M | -298 M |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Apellis Pharmaceuticals
APLS
|
-3.01 B | $ 20.41 | -1.4 % | $ 2.57 B |  USA |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Aptorum Group Limited
APM
|
-72.4 M | $ 0.79 | -6.51 % | $ 4.31 M |  China |
 |
Axsome Therapeutics
AXSM
|
-1.31 B | $ 165.07 | -0.79 % | $ 8.21 B | USA |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M | China |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
AbCellera Biologics
ABCL
|
-29.5 M | $ 3.76 | -1.7 % | $ 1.12 B |  Canada |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Corvus Pharmaceuticals
CRVS
|
-335 M | $ 18.11 | 1.23 % | $ 870 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-1.07 B | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acer Therapeutics
ACER
|
-141 M | - | 2.71 % | $ 14 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-224 M | - | - | $ 2.17 B | USA |
 |
Acorda Therapeutics
ACOR
|
-1.19 B | - | -24.86 % | $ 820 K | USA |
 |
Capricor Therapeutics
CAPR
|
-159 M | $ 26.36 | -1.82 % | $ 706 M | USA |
 |
Certara
CERT
|
-130 M | $ 7.24 | 2.62 % | $ 1.16 B | USA |
 |
Acasti Pharma
ACST
|
-221 M | - | 4.01 % | $ 150 M | Canada |
 |
Codexis
CDXS
|
-563 M | $ 1.01 | -0.98 % | $ 74.1 M | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-131 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-223 M | - | 1.93 % | $ 17.4 M | USA |
 |
Catalyst Pharmaceuticals
CPRX
|
474 M | $ 23.77 | -0.46 % | $ 2.91 B | USA |
 |
Agenus
AGEN
|
-1.96 B | $ 3.27 | -2.09 % | $ 1.17 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
-149 M | - | - | $ 7.46 M |  Israel |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Agios Pharmaceuticals
AGIO
|
-562 M | $ 28.85 | -1.2 % | $ 1.67 B | USA |
 |
Champions Oncology
CSBR
|
-79.9 M | $ 5.98 | -1.48 % | $ 81.7 M | USA |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Завод ДИОД
DIOD
|
1.21 B | - | - | - | Russia |
 |
Фармсинтез
LIFE
|
-3.54 B | - | - | - | Russia |
 |
Albireo Pharma
ALBO
|
-301 M | - | -0.23 % | $ 916 M | USA |
 |
Cellectis S.A.
CLLS
|
-506 M | $ 3.71 | -2.43 % | $ 116 M | France |
 |
Alector
ALEC
|
-972 M | $ 2.13 | -3.39 % | $ 219 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-246 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aileron Therapeutics
ALRN
|
-351 M | - | 10.36 % | $ 9.8 M | USA |
 |
Altimmune
ALT
|
-561 M | $ 4.22 | 1.32 % | $ 300 M | USA |
 |
Teligent, Inc.
TLGT
|
-121 M | - | -13.85 % | $ 16.1 M | USA |
 |
AlloVir
ALVR
|
-715 M | - | 4.14 % | $ 49.1 M | USA |
 |
Viela Bio, Inc.
VIE
|
-427 M | - | - | $ 2.91 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
Amarin Corporation plc
AMRN
|
-1.71 B | $ 14.3 | 2.66 % | $ 5.93 B |  Irlanda |
 |
AbbVie
ABBV
|
-15.5 B | $ 233.44 | -0.33 % | $ 413 B | USA |